NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO

NovoCure Ltd

CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.
CFO Ashley Cordova named CEO effective Jan 1, 2025; she will stay as CFO until successor appointed.
COO Wilco Groenhuysen resigns effective Oct 1, 2024; Mukund Paravasthu promoted to COO.
Groenhuysen entered new employment agreement: base salary $615K/yr to Sept 2025 then $120K/yr to Apr 2026.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Ashley Cordova

Chief Executive Officer

NVCR · NovoCure Ltd

Effective: 2025-01-01
Filed: September 3, 2024, 7:59 PM ET

On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.

Role change

Wilco Groenhuysen

Senior Advisor

NVCR · NovoCure Ltd

Effective: 2024-10-01
Filed: September 3, 2024, 7:59 PM ET

On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.

Role change

Asaf Danziger

Senior Advisor

NVCR · NovoCure Ltd

Effective: 2025-01-01
Successor: Ashley Cordova
Filed: September 3, 2024, 7:59 PM ET

On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ashley Cordova was appointed as Chief Executive Officer at NovoCure Ltd.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Wilco Groenhuysen resigned as Senior Advisor at NovoCure Ltd.

Action: resigned
Role: Senior Advisor

Exact text from the filing

On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Asaf Danziger resigned as Senior Advisor at NovoCure Ltd.

Action: resigned
Role: Senior Advisor

Exact text from the filing

On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.